Balyasny Asset Management
ATRS

Balyasny Asset Management’s Antares Pharma, Inc. ATRS Stock Holding History

Balyasny Asset Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-33,179
Closed -$145K – 2610
2021
Q2 		$145K Buy
33,179
+16,406
+98% +$66.8K ﹤0.01% 1765
2021
Q1 		$69K Buy
+16,773
New +$72.7K ﹤0.01% 1664
2018
Q1 		– Sell
-43,950
Closed -$87K – 2440
2017
Q4 		$87K Buy
+43,950
New +$95.6K ﹤0.01% 1985
2015
Q2 		– Sell
-24,960
Closed -$68K – 1391
2015
Q1 		$68K Buy
+24,960
New +$63.3K ﹤0.01% 909

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Balyasny Asset Management's ATRS Position: Q3 2021 in Review

Balyasny Asset Management sold out of Antares Pharma, Inc. (ATRS) in Q3 2021, closing a stake of 33,179 shares — an estimated $145K sold.

Balyasny Asset Management first reported a position in ATRS in Q1 2015 and held it in 4 quarters. The position peaked at $145K in Q2 2021. 170 funds tracked by Wall St. Rank hold ATRS as of Q3 2021.

  • Balyasny Asset Management reported no remaining Antares Pharma, Inc. position as of Q3 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 33,179 Antares Pharma, Inc. shares in Q3 2021, an estimated $145K.
  • Balyasny Asset Management first reported a position in Antares Pharma, Inc. in Q1 2015 and held it in 4 quarters.
  • Balyasny Asset Management's Antares Pharma, Inc. position peaked at $145K in Q2 2021.
  • 170 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.